M

Mabwell Shanghai Bioscience Co Ltd
SSE:688062

Watchlist Manager
Mabwell Shanghai Bioscience Co Ltd
SSE:688062
Watchlist
Price: 46.02 CNY 0.55% Market Closed
Market Cap: 18.4B CNY

Wall Street
Price Targets

Price Targets Summary
Mabwell Shanghai Bioscience Co Ltd

There are no price targets for Mabwell Shanghai Bioscience Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Mabwell Shanghai Bioscience Co Ltd Competitors:
Price Targets
LTRN
Lantern Pharma Inc.
485% Upside
603087
Gan & Lee Pharmaceuticals
7% Downside
688331
RemeGen Co Ltd
2% Downside
PTGX
Protagonist Therapeutics Inc
20% Upside
096530
Seegene Inc
75% Upside
1801
Innovent Biologics Inc
20% Upside
EDT
Spectral Medical Inc
118% Upside
HPHA
Heidelberg Pharma AG
75% Upside

Revenue
Forecast

Revenue Estimate
Mabwell Shanghai Bioscience Co Ltd

For the last 5 years the compound annual growth rate for Mabwell Shanghai Bioscience Co Ltd's revenue is 47%. The projected CAGR for the next 3 years is 119%.

47%
Past Growth
119%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Mabwell Shanghai Bioscience Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Mabwell Shanghai Bioscience Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Mabwell Shanghai Bioscience Co Ltd's stock price target?
Not Available

Mabwell Shanghai Bioscience Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Mabwell Shanghai Bioscience Co Ltd's Revenue forecast?
Projected CAGR
119%

For the last 5 years the compound annual growth rate for Mabwell Shanghai Bioscience Co Ltd's revenue is 47%. The projected CAGR for the next 3 years is 119%.

Back to Top